Hester rises on getting manufacturing license for Inactivated Avian Influenza Vaccine for poultry
Hester Biosciences is currently trading at Rs. 1390.00, up by 8.40 points or 0.61% from its previous closing of Rs. 1381.60 on the BSE.
The scrip opened at Rs. 1389.00 and has touched a high and low of Rs. 1390.00 and Rs. 1371.85 respectively. So far 104 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2347.70 on 04-Aug-2025 and a 52 week low of Rs. 1246.75 on 28-Mar-2025.
Last one week high and low of the scrip stood at Rs. 1516.30 and Rs. 1371.85 respectively. The current market cap of the company is Rs. 1167.01 crore.
The promoters holding in the company stood at 53.73%, while Institutions and Non-Institutions held 0.51% and 45.76% respectively.
Hester Biosciences has received the manufacturing license from the Food & Drugs Control Administration to manufacture and market the Low Pathogenic Avian Influenza Vaccine, Inactivated H9N2 strain for poultry. Low Pathogenic Avian Influenza H9N2 strain has been a persistent challenge in poultry flocks and is known to cause year-round comorbidity, leading to significant economic losses. H9N2 can lead to an irreversible drop in egg production in layers and performance loss in broilers. It can also lead to high mortality in the presence of other infections.
This license is a key regulatory step in advancing the company’s prevention-led poultry healthcare portfolio. This vaccine has been developed from technology acquired from ICAR-NIHSAD via Agrinnovate India.
Hester Biosciences (Hester) is the largest poultry vaccine manufacturer and one of the leading animal healthcare companies in India.
